KILEN was created in 1992 but their co-workers had already a long history of working with pharmaceutical drug dependency when it in the 1960s became clear that the new benzodiazepines were causing dependency and harm. with focus on common psychiatric side effects related to antidepressant usage. More than one ADR for a specific drug could be reported. Results In total 665 reports were Khasianine made during the period. 442 reports concerned antidepressant medications and the individual antidepressant reports represented 2392 ADRs and 878 (37%) of these were psychiatric ADRs. 75% of the individual reports concerned serotonin-reuptake inhibitor (SSRI) and the rest serotonin-norepinephrine reuptake inhibitor (SNRI). Women reported more antidepressant psychiatric ADRs (71%) compared to men (24%). More potentially serious psychiatric ADRs were frequently reported to KILEN and withdrawal symptoms during discontinuation were also reported as a common issue. Conclusions The present study indicates that consumer reports may contribute with important information regarding more serious psychiatric ADRs following antidepressant treatment. Consumer reporting may be considered a complement to traditional ADR reporting. Background The World Health Organization (WHO) argues that the cost of adverse drug reactions (ADRs) in the general population (in developed countries) is high . Pharmacoeconomic studies from 1997 and 1998 have estimated that ADRs may lead to an additional $1.56 to $4 billion in direct hospital costs per year in the United States [2-4]. These estimations are however uncertain and in most countries the extent of this expenditure has not been measured. The reporting of potential ADRs by healthcare professionals is supported by WHO and their Drug Monitoring Programme , and under-reporting by health professionals is a well-recognized problem by the WHO . Another way to increase ADR reporting could be to let the consumers themselves report directly to the Khasianine authorities. One important step towards consumer reporting of ADRs was recently taken by the European Parliament, who in September 2010 voted in BTD favor for a new pharmacovigilance legislation to ensure greater patient safety and to improve public health [7,8]. This was later cleared by the European Council in December 2010 . The new legislation came into force on 1 January 2011 but will not apply until July 2012 [7,9]. Member States will then have to adopt these changes in order to harmonize national adverse event systems, and one important change to the current law foresees the inclusion of direct patient Khasianine reporting (DPR) of adverse events . Some mean that this will mark the beginning of a new chapter in drug safety . The WHO acknowledges that it is not always easy to recognize ADRs (which may act through the same physiological and pathological pathways as different diseases) and proposes a step-wise procedure to assessing possible drug-related ADRs . Therefore, the organization proclaims consumer reporting to be of great importance in order to safeguard a pharmacovigilance that will help each patient to receive optimum therapy, and on a population basis will lead to ensure the acceptance and effectiveness of public health programmes . Consumers in both the Netherlands and Denmark have had the possibility to report ADRs to their authorities since 2003. Different studies have shown that ADRs reported by patients has the potential to increase knowledge about the possible harm of medicines . A Danish study of reports to the Danish Medicines Agency Khasianine (DKMA) showed for instance that patients are more likely to report ADRs from the nervous and psychiatric system than are health professionals . A Dutch study indicated that patients seem to report different experiences compared to healthcare professionals regarding ADRs from antidepressants , and that patients now take great interest in their drug use and often search for more information about their own medication and often focus on ADRs . Withdrawal symptoms are according to an English study described in a clearer way by consumer reports compared to how.